Literature DB >> 6138714

Plasma insulin levels and beta-adrenoceptor antagonists. Relevance of the steric configuration of beta-adrenoceptor antagonists to their effect on glucose tolerance.

A Beck, W Conca, S Bacher, G Raberger.   

Abstract

The relevance of the steric configuration to the effects of two non-selective beta-adrenoceptor antagonists without intrinsic sympathomimetic activity (+)- and (--)-bupranolol (10 and 50 micrograms/kg i.v.) and (4)- and (--)-propranolol (100 and 500 micrograms/kg i.v.) on the i.v. glucose tolerance test (IVGTT) were investigated in conscious, normoglycemic dogs. The effects of the beta-adrenoceptor antagonists on plasma glucose, and insulin levels and insulin-glucagon ratio following IVGTT were evaluated by calculating the respective areas under the curve (AUC). The AUC values for plasma glucose were significantly increased by the (--)-configuration of both beta-adrenoceptor increased by the (--)-configuration of both beta-adrenoceptor antagonists. In the (+)-configuration only propranolol (500 micrograms/kg i.v.) increased the AUC value for plasma glucose significantly. The AUC values for plasma insulin and also for the plasma insulin-glucagon ratio were significantly increased by (--)-propranolol (500 micrograms/kg i.v.) and by (--)-bupranolol (10 and 50 micrograms/kg i.v.). Thus the impairment of glucose tolerance, due to suppression of the plasma insulin level, depends mainly on the beta-adrenoceptor antagonistic activity of the (--)-configuration.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6138714     DOI: 10.1007/bf00647837

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  18 in total

1.  Microdetermination of long-chain fatty acids in plasma and tissues.

Authors:  V P DOLE; H MEINERTZ
Journal:  J Biol Chem       Date:  1960-09       Impact factor: 5.157

2.  Autonomic control of insulin secretion and the treatment of heart failure.

Authors:  P A Majid; C Saxton; J R Dykes; M C Galvin; S H Taylor
Journal:  Br Med J       Date:  1970-11-07

3.  Inhibition of insulin secretion by aryl-substituted secondary aminoethanols.

Authors:  R Bressler; M Vargas-Cordon; K Brendel
Journal:  Diabetes       Date:  1969-05       Impact factor: 9.461

4.  Beta-adrenergic stimulation and insulin release in dogs following HB 419.

Authors:  O V Sirek; M Vigas; A Niki; H Niki; A Sirek
Journal:  Diabetologia       Date:  1969-08       Impact factor: 10.122

5.  Effects of selective and non-selective beta-adrenergic agents on insulin secretion in vivo.

Authors:  B Ahrén; I Lundquist
Journal:  Eur J Pharmacol       Date:  1981-04-24       Impact factor: 4.432

6.  Plasma insulin levels and beta-adrenoceptor antagonists. The effects of cardioselective and non-cardioselective beta-adrenoceptor antagonists with and without intrinsic sympathomimetic activity on basal insulin level and insulin level after glucose stimulation in normoglycemic dogs.

Authors:  W Conca; A Beck; S Bacher; G Raberger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-07       Impact factor: 3.000

7.  The effect of beta-blockade on glucose tolerance and insulin release in adult diabetes.

Authors:  G Holm; S Johansson; A Vedin; C Wilhelmsson; U Smith
Journal:  Acta Med Scand       Date:  1980

8.  Effects of autonomic blockade by methylatropine and optical isomers and propranolol on plasma insulin levels in the basal state and after stimulation.

Authors:  B Ahrén; I Lundquist
Journal:  Acta Physiol Scand       Date:  1981-05

9.  Effect of adrenergic-blocking or -stimulating agents on plasma growth hormone, immunoreactive insulin, and blood free fatty acid levels in man.

Authors:  H Imura; Y Kato; M Ikeda; M Morimoto; M Yawata
Journal:  J Clin Invest       Date:  1971-05       Impact factor: 14.808

10.  Insulin antagonistic effects of epinephrine and glucagon in the dog.

Authors:  L Saccà; N Eigler; P E Cryer; R S Sherwin
Journal:  Am J Physiol       Date:  1979-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.